Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like Telix Pharma, Release: Companies Conclude Therapeutic Product Development Agreement For Prostate Cancer January 18, 2017 Bristol-Myers, Johnson & Johnson Get in on Europeon Biotech Fund's $95M Raise October 30, 2017 These 3 Gene Therapy Biotechs Could Make Investors Rich October 22, 2017
Telix Pharma, Release: Companies Conclude Therapeutic Product Development Agreement For Prostate Cancer January 18, 2017
